Hormone Receptor-Positive Metastatic Breast Cancer — An Interview with Dr Adam M Brufsky on the Impact of Biomarkers and Existing Comorbidities on the Selection of First-Line Therapy (Companion Faculty Lecture)

Featuring a slide presentation and related discussion from Dr Adam M Brufsky, including the following topics:

• Mechanism of action of and long-term data with CDK4/6 inhibitors in the management of metastatic breast cancer (mBC) (0:00)
• Comparing safety profiles of CDK4/6 inhibitors (9:49)
• Role of CDK4/6 inhibitors in therapy for older patients with mBC (24:06)
• Real-world evidence with CDK4/6 inhibitors (27:31)

CME information and select publications